201. Comparison of the efficacy among multiple chemotherapeutic interventions combined with radiation therapy for patients with cervix cancer after surgery: A network meta-analysis
- Author
-
Ruixia Guo and Lei Chang
- Subjects
0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,efficacy ,Network Meta-Analysis ,Uterine Cervical Neoplasms ,chemotherapy ,cervix cancer ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Odds Ratio ,Humans ,radiotherapy ,Cisplatin ,Postoperative Care ,Chemotherapy ,Ifosfamide ,business.industry ,Cancer ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Surgery ,Radiation therapy ,030104 developmental biology ,Treatment Outcome ,Oncology ,Docetaxel ,Fluorouracil ,030220 oncology & carcinogenesis ,Retreatment ,Disease Progression ,Female ,Radiotherapy, Adjuvant ,business ,medicine.drug ,Epirubicin ,Research Paper - Abstract
// Lei Chang 1 and Ruixia Guo 1 1 Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China Correspondence to: Lei Chang, email: nancy_lei7985@163.com Keywords: cervix cancer, radiotherapy, chemotherapy, efficacy, network meta-analysis Received: November 24, 2016 Accepted: February 15, 2017 Published: April 20, 2017 ABSTRACT Background: Cervix cancer was the second most common cancer in female. However, there was no network meta-analysis (NMA) comparing the efficacy of the multiple chemotherapeutic interventions combined with radiation therapy in patients after operation. Methods: Randomized controlled trials were retrieved from PubMed, Embase and Cochrane Library. Overall survival (OS), recurrence-free survival (RFS), incidence of recurrence and distant metastasis were the main outcomes, particularly 5-year OS and PFS were considered as primary outcomes. Furthermore, the hazard ratio (HR) or odds ratio (OR) and their 95% credible intervals (CrIs) were extracted. The surface under cumulative ranking curve (SUCRA) was also used in this NMA. Results: A total of 39 eligible trials with 8,952 patients were included and 22 common chemotherapies were evaluated in this meta-analysis. For OS, cisplatin+fluorouracil+hydroxyurea, fluorouracil+mitomycin C, cisplatin and cisplatin+fluorouracil were better than placebo. As for RFS, cisplatin+fluorouracil, fluorouracil+mitomycin C, and cisplatin alone had the significant superiority compared with placebo. In terms of incidence of recurrence, the optimal drug combination was cisplatin+ifosfamide (0.93) based on SUCRA. Moreover, epirubicin (OR = 0.28, 95% CrI: 0.08-0.91) was the only one had the distinguished potency in reducing the occurrence of distant metastasis with a SUCRA rank probability of 0.88. Conclusion: We recommended cisplatin+fluorouracil+hydroxyurea and cisplatin+docetaxel for their good efficacy in long term survival. Meanwhile, the combination of multiple drugs with different mechanisms worked better.
- Published
- 2017